FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1850849049> ?p ?o ?g. }

• W1850849049 endingPage "e0133146" @default.
• W1850849049 startingPage "e0133146" @default.
• W1850849049 abstract "Background Ultramarathon is a high endurance exercise associated with a wide range of exercise-related problems, such as acute kidney injury (AKI). Early recognition of individuals at risk of AKI during ultramarathon event is critical for implementing preventative strategies. Objectives To investigate the impact of speed variability to identify the exercise-related acute kidney injury anticipatively in ultramarathon event. Methods This is a prospective, observational study using data from a 100 km ultramarathon in Taipei, Taiwan. The distance of entire ultramarathon race was divided into 10 splits. The mean and variability of speed, which was determined by the coefficient of variation (CV) in each 10 km-split (25 laps of 400 m oval track) were calculated for enrolled runners. Baseline characteristics and biochemical data were collected completely 1 week before, immediately post-race, and one day after race. The main outcome was the development of AKI, defined as Stage II or III according to the Acute Kidney Injury Network (AKIN) criteria. Multivariate analysis was performed to determine the independent association between variables and AKI development. Results 26 ultramarathon runners were analyzed in the study. The overall incidence of AKI (in all Stages) was 84.6% (22 in 26 runners). Among these 22 runners, 18 runners were determined as Stage I, 4 runners (15.4%) were determined as Stage II, and none was in Stage III. The covariates of BMI (25.22 ± 2.02 vs. 22.55 ± 1.96, p = 0.02), uric acid (6.88 ± 1.47 vs. 5.62 ± 0.86, p = 0.024), and CV of speed in specific 10-km splits (from secondary 10 km-split (10th – 20th km-split) to 60th – 70th km-split) were significantly different between runners with or without AKI (Stage II) in univariate analysis and showed discrimination ability in ROC curve. In the following multivariate analysis, only CV of speed in 40th – 50th km-split continued to show a significant association to the development of AKI (Stage II) (p = 0.032). Conclusions The development of exercise-related AKI was not infrequent in the ultramarathon runners. Because not all runners can routinely receive laboratory studies after race, variability of running speed (CV of speed) may offer a timely and efficient tool to identify AKI early during the competition, and used as a surrogate screening tool, at-risk runners can be identified and enrolled into prevention trials, such as adequate fluid management and avoidance of further NSAID use." @default.
• W1850849049 created "2016-06-24" @default.
• W1850849049 creator A5009461632 @default.
• W1850849049 creator A5012434896 @default.
• W1850849049 creator A5025593335 @default.
• W1850849049 creator A5053022883 @default.
• W1850849049 creator A5053515127 @default.
• W1850849049 creator A5077319978 @default.
• W1850849049 creator A5083632547 @default.
• W1850849049 creator A5088567617 @default.
• W1850849049 date "2015-07-15" @default.
• W1850849049 modified "2023-09-25" @default.
• W1850849049 title "Clinical Impact of Speed Variability to Identify Ultramarathon Runners at Risk for Acute Kidney Injury" @default.
• W1850849049 cites W1544518547 @default.
• W1850849049 cites W174286142 @default.
• W1850849049 cites W1757757462 @default.
• W1850849049 cites W1967289589 @default.
• W1850849049 cites W1967300023 @default.
• W1850849049 cites W1972787024 @default.
• W1850849049 cites W1984902820 @default.
• W1850849049 cites W1985233592 @default.
• W1850849049 cites W1987882885 @default.
• W1850849049 cites W1989197339 @default.
• W1850849049 cites W1994487135 @default.
• W1850849049 cites W2013183840 @default.
• W1850849049 cites W2016596287 @default.
• W1850849049 cites W2017025388 @default.
• W1850849049 cites W2020799520 @default.
• W1850849049 cites W2038737991 @default.
• W1850849049 cites W2052077714 @default.
• W1850849049 cites W2074619411 @default.
• W1850849049 cites W2081007756 @default.
• W1850849049 cites W2094846833 @default.
• W1850849049 cites W2097738160 @default.
• W1850849049 cites W2100643880 @default.
• W1850849049 cites W2100833574 @default.
• W1850849049 cites W2102556842 @default.
• W1850849049 cites W2104656637 @default.
• W1850849049 cites W2121051159 @default.
• W1850849049 cites W2129493921 @default.
• W1850849049 cites W2136498264 @default.
• W1850849049 cites W2137671103 @default.
• W1850849049 cites W2138154057 @default.
• W1850849049 cites W2138331906 @default.
• W1850849049 cites W2184170234 @default.
• W1850849049 cites W2316092734 @default.
• W1850849049 cites W2323953755 @default.
• W1850849049 cites W2613483874 @default.
• W1850849049 doi "https://doi.org/10.1371/journal.pone.0133146" @default.
• W1850849049 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4701727" @default.
• W1850849049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26730598" @default.
• W1850849049 hasPublicationYear "2015" @default.
• W1850849049 type Work @default.
• W1850849049 sameAs 1850849049 @default.
• W1850849049 citedByCount "21" @default.
• W1850849049 countsByYear W18508490492016 @default.
• W1850849049 countsByYear W18508490492017 @default.
• W1850849049 countsByYear W18508490492018 @default.
• W1850849049 countsByYear W18508490492019 @default.
• W1850849049 countsByYear W18508490492020 @default.
• W1850849049 countsByYear W18508490492021 @default.
• W1850849049 countsByYear W18508490492022 @default.
• W1850849049 crossrefType "journal-article" @default.
• W1850849049 hasAuthorship W1850849049A5009461632 @default.
• W1850849049 hasAuthorship W1850849049A5012434896 @default.
• W1850849049 hasAuthorship W1850849049A5025593335 @default.
• W1850849049 hasAuthorship W1850849049A5053022883 @default.
• W1850849049 hasAuthorship W1850849049A5053515127 @default.
• W1850849049 hasAuthorship W1850849049A5077319978 @default.
• W1850849049 hasAuthorship W1850849049A5083632547 @default.
• W1850849049 hasAuthorship W1850849049A5088567617 @default.
• W1850849049 hasBestOaLocation W18508490491 @default.
• W1850849049 hasConcept C120665830 @default.
• W1850849049 hasConcept C121332964 @default.
• W1850849049 hasConcept C126322002 @default.
• W1850849049 hasConcept C188816634 @default.
• W1850849049 hasConcept C23131810 @default.
• W1850849049 hasConcept C2780472472 @default.
• W1850849049 hasConcept C38180746 @default.
• W1850849049 hasConcept C61511704 @default.
• W1850849049 hasConcept C71924100 @default.
• W1850849049 hasConceptScore W1850849049C120665830 @default.
• W1850849049 hasConceptScore W1850849049C121332964 @default.
• W1850849049 hasConceptScore W1850849049C126322002 @default.
• W1850849049 hasConceptScore W1850849049C188816634 @default.
• W1850849049 hasConceptScore W1850849049C23131810 @default.
• W1850849049 hasConceptScore W1850849049C2780472472 @default.
• W1850849049 hasConceptScore W1850849049C38180746 @default.
• W1850849049 hasConceptScore W1850849049C61511704 @default.
• W1850849049 hasConceptScore W1850849049C71924100 @default.
• W1850849049 hasIssue "7" @default.
• W1850849049 hasLocation W18508490491 @default.
• W1850849049 hasLocation W18508490492 @default.
• W1850849049 hasLocation W18508490493 @default.
• W1850849049 hasLocation W18508490494 @default.
• W1850849049 hasLocation W18508490495 @default.
• W1850849049 hasOpenAccess W1850849049 @default.
• W1850849049 hasPrimaryLocation W18508490491 @default.

• next